Search Results - "Shen, Yuqiao"

Discovery and Characterization of (8S,9R)‑5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl‑1H‑1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro‑3H‑pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent by Wang, Bing, Chu, Daniel, Feng, Ying, Shen, Yuqiao, Aoyagi-Scharber, Mika, Post, Leonard E

“…We discovered and developed a novel series of tetrahydro­pyrido­phthlazinones as poly­(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors. Lead optimization led…”
Get full text

Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma by Kizilbash, Sani H, Gupta, Shiv K, Chang, Kenneth, Kawashima, Ryo, Parrish, Karen E, Carlson, Brett L, Bakken, Katrina K, Mladek, Ann C, Schroeder, Mark A, Decker, Paul A, Kitange, Gaspar J, Shen, Yuqiao, Feng, Ying, Protter, Andrew A, Elmquist, William F, Sarkaria, Jann N

“…Poly ADP-ribose polymerase (PARP) inhibitors, including talazoparib, potentiate temozolomide efficacy in multiple tumor types; however, talazoparib-mediated…”
Get full text

Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China by Zhuang, Wei, Fan, Zheng, Chu, Yanqi, Wang, Haizheng, Yang, Ying, Wu, Li, Sun, Nan, Sun, Ge, Shen, Yuqiao, Lin, Xiaolan, Guo, Guiming, Xi, Shengyan

“…Coronavirus Disease 2019 (COVID-19) is an emerging and rapidly evolving disease, with no recommended effective anti-coronavirus drug treatment. Traditional…”
Get full text

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer by Allison Stewart, C, Tong, Pan, Cardnell, Robert J, Sen, Triparna, Li, Lerong, Gay, Carl M, Masrorpour, Fatemah, Fan, You, Bara, Rasha O, Feng, Ying, Ru, Yuanbin, Fujimoto, Junya, Kundu, Samrat T, Post, Leonard E, Yu, Karen, Shen, Yuqiao, Glisson, Bonnie S, Wistuba, Ignacio, Heymach, John V, Gibbons, Don L, Wang, Jing, Byers, Lauren Averett

“…Small cell lung cancer (SCLC) is one of the most aggressive forms of cancer, with a 5-year survival <7%. A major barrier to progress is the absence of…”
Get full text

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer by CARDNELL, Robert J, YING FENG, BYERS, Lauren A, LIXIA DIAO, FAN, You-Hong, MASRORPOUR, Fatemah, JING WANG, YUQIAO SHEN, MILLS, Gordon B, MINNA, John D, HEYMACH, John V

“…Small cell lung carcinoma (SCLC) is an aggressive malignancy affecting nearly 30,000 people annually in the United States. We have previously identified…”
Get full text

Substrate reduction therapy for Krabbe disease and metachromatic leukodystrophy using a novel ceramide galactosyltransferase inhibitor by Babcock, Michael C., Mikulka, Christina R., Wang, Bing, Chandriani, Sanjay, Chandra, Sundeep, Xu, Yue, Webster, Katherine, Feng, Ying, Nelvagal, Hemanth R., Giaramita, Alex, Yip, Bryan K., Lo, Melanie, Jiang, Xuntian, Chao, Qi, Woloszynek, Josh C., Shen, Yuqiao, Bhagwat, Shripad, Sands, Mark S., Crawford, Brett E.

“…Krabbe disease (KD) and metachromatic leukodystrophy (MLD) are caused by accumulation of the glycolipids galactosylceramide (GalCer) and sulfatide and their…”
Get full text

Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer by Cardnell, Robert J, Feng, Ying, Mukherjee, Seema, Diao, Lixia, Tong, Pan, Stewart, C Allison, Masrorpour, Fatemeh, Fan, YouHong, Nilsson, Monique, Shen, Yuqiao, Heymach, John V, Wang, Jing, Byers, Lauren A

“…Small cell lung cancer (SCLC) is an aggressive malignancy with limited treatment options. We previously found that PARP is overexpressed in SCLC and that…”
Get full text

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity by O'Shea, Clodagh C., Johnson, Leisa, Bagus, Bridget, Choi, Serah, Nicholas, Cory, Shen, Annie, Boyle, Larry, Pandey, Kusum, Soria, Conrado, Kunich, John, Shen, Yuqiao, Habets, Gaston, Ginzinger, Dave, McCormick, Frank

“…ONYX-015 is an adenovirus that lacks the E1B-55K gene product for p53 degradation. Thus, ONYX-015 was conceived as an oncolytic virus that would selectively…”
Get full text

Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA by ZHANG, Yu-An, NEMUNAITIS, John, SAMUEL, Shirley K, CHEN, Patrick, YUQIAO SHEN, TONG, Alex W

“…Despite successes in animal models, cancer gene therapy with small interfering RNAs (siRNA) is hindered by the lack of an optimal delivery platform. We…”
Get full text

BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency by YUQIAO SHEN, REHMAN, Farah L, YING FENG, BOSHUIZEN, Julia, BAJRAMI, Ilirjana, ELLIOTT, Richard, BING WANG, LORD, Christopher J, POST, Leonard E, ASHWORTH, Alan

“…PARP1/2 inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair. Here, we describe BMN 673, a novel, highly potent PARP1/2…”
Get full text

Trapping Poly(ADP-Ribose) Polymerase by Shen, Yuqiao, Aoyagi-Scharber, Mika, Wang, Bing

“…Recent findings indicate that a major mechanism by which poly(ADP-ribose) polymerase (PARP) inhibitors kill cancer cells is by trapping PARP1 and PARP2 to the…”
Get more information

Human Cytomegalovirus IE1 and IE2 Proteins are Mutagenic and Mediate ``Hit-And-Run" Oncogenic Transformation in Cooperation with the Adenovirus E1A Proteins by Shen, Yuqiao, Zhu, Hua, Shenk, Thomas

“…Some epidemiological studies have suggested a possible link between human cytomegalovirus (HCMV) infection and various malignancies, and HCMV has been shown to…”
Get full text

Analyses of Single-Amino-Acid Substitution Mutants of Adenovirus Type 5 E1B-55K Protein by Shen, Y, Kitzes, G, Nye, J A, Fattaey, A, Hermiston, T

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Developing Novel Oncolytic Adenoviruses through Bioselection by Yan, Wen, Kitzes, Galila, Dormishian, Farid, Hawkins, Lynda, Sampson-Johannes, Adam, Watanabe, Josh, Holt, Jenny, Lee, Vivian, Dubensky, Thomas, Fattaey, Ali, Hermiston, Terry, Balmain, Allan, Shen, Yuqiao

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition by Murai, Junko, Feng, Ying, Yu, Guoying K, Ru, Yuanbin, Tang, Sai-Wen, Shen, Yuqiao, Pommier, Yves

“…Poly(ADP-ribose) polymerase inhibitors (PARPIs) kill cancer cells by trapping PARP1 and PARP2. Talazoparib, the most potent PARPI inhibitor (PARPI), exhibits…”
Get full text

Development of AL01211, a Novel Glucosylceramide Synthase Inhibitor, to Treat Autosomal Dominant Polycystic Kidney Disease (ADPKD): PO1198 by Babcock, Michael C., Zheng, Jianhong, Li, Li, Mei, Changlin, Garovoy, Marvin R., Shen, Yuqiao

Get full text

Red-emitting enhancement of Bi4Si3O12:Sm3+ phosphor by Pr3+ co-doping for White LEDs application by Shen, Yuqiao, Qiu, Kehui, Zhang, Wentao, Zeng, Yu

“…In this account, Bi4Si3O12:Sm3+ and (Bi4Si3O12:Sm3+, Pr3+) red phosphors were prepared by solution combustion method fueled by citric acid at 900°C for 1h. The…”
Get full text

Use of Proteomics Analysis for Molecular Precision Approaches in Cancer Therapy by Shen, Yuqiao, Senzer, Neil N., Nemunaitis, John J.

“…Yuqiao Shen1, Neil N. Senzer1,2 and John J. Nemunaitis2 1LEAD Therapeutics, Inc., San Bruno, CA. 2Mary Crowley Cancer Research Centers, Dallas, TX. Abstract…”
Get full text

Synthesis of Dy3+ co-doped Bi4Si3O12:Sm3+ phosphors with enhanced red-emitting properties by Shen, Yuqiao, Qiu, Kehui, Wang, Junlan, Zhang, Wentao, Tang, Qinxue

“…[Bi4Si3O12:Sm3+, Dy3+] samples were prepared by the chemical solution decomposition method. The effects of different Bi3+ and Si4+ ion ratio in solution, as…”
Get full text

Use of Proteomics Analysis for Molecular Precision Approaches in Cancer Therapy by Shen, Yuqiao, Senzer, Neil N., Nemunaitis, John J.

“…Abstract non disponibile…”
Get full text